RIZATRIPTAN

GENERIC NAME: Rizatriptan benzoate

PHARMACOLOGICAL CLASS: Serotonin 5-HT-Receptor Agonists; Antimigraine
Agents
ATC CODE: N02CC04
PRACTICE INSIGHTS:

Patients taking propranolol: Limit dose to 5 mg PO and do not exceed 15 mg/24

hr
DOSE
ADULT:
Migraine Headache
Oral

5-10 mg at onset of symptoms; repeat dose after 2 hours if necessary; not to

exceed 30 mg/24 hr

PEDIATRIC:
Migraine Headache
Oral

<6 years: Safety and efficacy not established

6-17 years (<40 kg): 5 mg OD

6-17 years: (40 kg or greater): 10 mg OD

DOSE ADJUSTMENT
Hepatic impairment

No dosage adjustment provided in manufacturers labeling

Renal impairment

No dosage adjustment provided in manufacturers labeling

INDICATIONS (OPTIONAL):
PREGNANCY & LACTATION:

Category C
Excreting in breast milk unknown; use with caution in breastfeeding

MODE OF ACTION: It causes vasoconstriction and reduces inflammation associated

with antidromic neuronal transmission linked to relief of migraine
ADVERSE DRUG REACTIONS:
>10%

Dizziness , drowsiness, fatigue

1-10%

Asthenia, chest pain , dizziness, dry mouth ,dyspnea , headache h,ot

flashes,hypoesthesia, pain/pressure in chest, neck, throat, jaw, palpations,
paresthesia, skin flushing somnolence

<1%

Angioedema, arrhythmias, bradycardia, epidermal necrolysis, hallucination,

hearing impairment, hypertensive crisis, myocardial infarction and coronary
artery vasospasm in patients with cad risk factors, tachycardia, wheezing

DRUG INTERACTIONS:
CONTRAINDICATIONS & WARNINGS:

o
o

Contraindicated in
o Hypersensitivity
o Ischemic heart disease, uncontrolled hypertension, or other significant
cardiovascular disease
o Coronary artery vasospasm
o Peripheral vascular disease
o Basilar or hemiplegic migraine
o History of stroke or transient ischemic attack
o Ischemic bowel
o Within 24 hours of another 5-HT1 agonist or ergot derivative
o Within 2 weeks of MAOI
Risk of
Cerebral/subarachnoid hemorrhage and stroke
Use caution in
Hepatic/renal insufficiency
Phenylketonuria

DIETARY & GENERAL CONSIDERATIONS:

Advise patient to peel back blister pack with dry hands and place tablet on tong
ue. Tell him to s
Wallow drug with saliva only, not beverages.
Instruct female patient to immediately report possible pregnancy.

MONITORING PARAMETERS:

Monitor:
o vital signs
o cardiovascular status